Abstract
Background: The aim of this study was to identify novel binding partners for α-actinin-4 (actinin-4), an essential component of the glomerular filtration barrier.Methods: We performed bacterial two-hybrid screenings of a human kidney cDNA library using as a bait human actinin-4 containing the spectrin-like repeat R1. The identified interactions were further verified by in vitro affinity assays. To investigate the expression of the identified molecules in the kidney and other tissues, a human tissue cDNA panel screening and in situ hybridization were performed. Results: One isolated cDNA from the library encoded OK/SW-CL.16 protein with a segment similar to known actinin-interacting regions. OK/SW-CL.16 protein also contained the class I PxxP motif, which can participate in binding to Src homology 3 (SH3) domain-containing signaling proteins. In vitro affinity assays showed interactions of recombinant actinin-4 R1 and full-length renal actinin-4 with recombinant OK/SW-CL.16 protein. A tissue cDNA panel screening revealed a ubiquitous expression of OK/SW-CL.16 mRNA.In situ hybridization showed glomerular expression of OK/SW-CL.16 mRNA, mainly in podocytes and mesangial cells. Conclusion: Our results suggest that OK/SW-CL.16 protein is a novel binding partner for actinin-4. OK/SW-CL16 protein might act as a linker between actinin-4 and some SH3 domain-containing signaling proteins in podocytes.
Journal Section:
Original Paper
References
1.
Tryggvason K, Patrakka J, Wartiovaara J: Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 2006;354:1387–1401.
[PubMed]
2.
Benzing T: Signaling at the slit diaphragm. J Am Soc Nephrol 2004;15:1382–1391.
[PubMed]
3.
Gilmore AP, Parr T, Patel B, Gratzer WB, Critchley DR: Analysis of the phasing of four spectrin-like repeats in α-actinin. Eur J Biochem 1994;225:235–242.
[PubMed]
4.
Otey CA, Carpen O: Alpha-actinin revisited: a fresh look at an old player. Cell Motil Cytoskeleton 2004;58:104–111.
[PubMed]
5.
Honda K, Yamada T, Endo R, Ino Y, Gotoh M, Tsuda T, Yamada Y, Chiba H, Hirohashi S: Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J Cell Biol 1998;140:1383–1393.
[PubMed]
6.
Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong H-Q, Mathis BJ, Rodríguez-Pérez J-C, Allen PG, Beggs AH, Pollak MR: Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomerulosclerosis. Nature Genet 2000;24:251–256.
[PubMed]
7.
Yao J, Le TC, Kos CH, Henderson JM, Allen PG, Denker BM, Pollak MR: Alpha-actinin-4-mediated FSGS: an inherited kidney disease caused by an aggregated and rapidly degraded cytoskeletal protein. PLoS Biol 2004;2:787–794.
8.
Michaud J-L, Lemieux LI, Dubé M, Vanderhyden BC, Robertson SJ, Kennedy CRJ: Focal and segmental glomerulosclerosis in mice with podocyte-specific expression of mutant α-actinin-4. J Am Soc Nephrol 2003;14:1200–1211.
[PubMed]
9.
Kos CH, Le TC, Sinha S, Henderson JM, Kim SH, Sugimoto H, Kalluri R, Gerszten RE, Pollak MR: Mice deficient in α-actinin-4 have severe glomerular disease. J Clin Invest 2003;111:1683–1690.
[PubMed]
10.
Weins A, Kenlan P, Herbert S, Le TC, Villegas I, Kaplan BS, Appel GB, Pollak MR: Mutational and biological analysis of α-actinin-4 in focal segmental glomerulosclerosis. J Am Soc Nephrol 2005;16:3694–3701.
[PubMed]
11.
Djinovic-Carugo K, Gautel M, Ylänne J, Young P: The spectrin repeat: a structural platform for cytoskeletal protein assemblies. FEBS Lett 2002;513:119–123.
[PubMed]
12.
Goto H, Wakui H, Komatsuda A, Ohtani H, Imai H, Sawada K, Kobayashi R: Renal α-actinin-4: purification and puromycin aminonucleoside-binding property. Nephron Exp Nephrol 2003;93:e27–e35.
[PubMed]
13.
Kigawa A, Wakui H, Maki N, Okuyama S, Masai R, Ohtani H, Komatsuda A, Suzuki D, Toyoda M, Kobayashi R, Sawada K: Interaction of the spectrin-like repeats of α-actinin-4 with humanin peptide. Clin Exp Nephrol 2004;8:331–338.
[PubMed]
14.
Salmikangas P, Mykkänen O-M, Grönholm M, Heiska L, Kere J, Carpén O: Myotilin, a novel sarcomeric protein with two Ig-like domains, is encoded by a candidate gene for limb-girdle muscular dystrophy. Hum Mol Genet 1999;8:1329–1336.
[PubMed]
15.
Rönty M, Taivainen A, Moza M, Otey CA, Carpén O: Molecular analysis of the interaction between palladin and α-actinin. FEBS Lett 2004;566:30–34.
[PubMed]
16.
Mayer BJ: SH3 domains: complexity in moderation. J Cell Sci 2001;114:1253–1263.
[PubMed]
17.
Li SS: Specificity and versatility of SH3 and other proline-recognition domains: structural basis and implications for cellular signal transduction. Biochem J 2005;390:641–653.
[PubMed]
18.
Johnson S, Halford S, Morris AG, Patel RJ, Wilkie SE, Hardcastle AJ, Moore AT, Zhang K, Hunt DM: Genomic organisation and alternative splicing of human RIM1, a gene implicated in autosomal dominant cone-rod dystrophy (CORD7). Genomics 2003;81:304–314.
[PubMed]
19.
Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680–685.
[PubMed]
20.
Uehara G, Suzuki D, Toyoda M, Umezono T, Sakai H: Glomerular expression of platelet-derived growth factor (PDGF)-A, -B chain and PDGF receptor-α, -β in human diabetic nephropathy. Clin Exp Nephrol 2004;8:36–42.
[PubMed]
21.
Ylänne J, Scheffzek K, Young P, Saraste M: Crystal structure of the α-actinin rod reveals an extensive torsional twist. Structure 2001;9:597–604.
[PubMed]
22.
Hibino H, Pironkova R, Onwumere O, Vologodskaia M, Hudspeth AJ, Lesage F: RIM binding proteins (RBPs) couple Rab3-interacting molecules (RIMs) to voltage-gated Ca2+ channels. Neuron 2002;34:411–423.
[PubMed]
23.
Ishino T, Kobayashi R, Wakui H, Fukushima Y, Nakamoto Y, Miura AB: Biochemical characterization of contractile proteins of rat cultured mesangial cells. Kidney Int 1991;39:1118–1124.
[PubMed]
© 2007 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2007
You do not currently have access to this content.
